Abstract:As the first member of the solute carrier 6 (SLC6) protein family, the γ-aminobutyric acid (GABA) transporter 1 (GAT1, SLC6A1 ), plays a pivotal role in the uptake of GABA from the synaptic cleft into neurons and astrocytes. This process facilitates the subsequent storage of GABA in presynaptic vesicles. The human SLC6A1 gene is highly susceptible to missense mutations, leading to severe clinical outcomes, such as epilepsy, in the afflicted patients. The molecular mechanisms of SLC6A1 -associated disorders are discerned to some degree; many SLC6A1 mutations are now known to impair protein folding, and consequently fail to reach the plasma membrane. Inherently, once inside the endoplasmic reticulum (ER), GAT1 abides by a complex cascade of events that enable efficient intracellular trafficking. This involves association with specialized molecular chaperones responsible for steering the protein folding process, oligomerization, sorting through the Golgi apparatus, and ultimately delivery to the cell surface. The entire process is subject to stringent quality control mechanisms at multiple checkpoints. While the majority of the existing loss-of-function SLC6A1 variants interfere with folding and membrane targeting, certain mutants retain abundant surface expression. In either scenario, suppressed GAT1 activity disrupts GABAergic neurotransmission, preceding the disease manifestation in individuals harboring these mutations. The nervous system is enthralling and calls for systematic, groundbreaking research efforts to dissect the precise molecular factors associated with the onset of complex neurological disorders, and uncover additional non-canonical therapeutic targets. Recent research has given hope for some of the misfolded SLC6A1 variants, which can be salvaged by small molecules, i.e., chemical and pharmacological chaperones, acting on multiple upstream targets in the secretory pathway. We here highlight the significance of pharmacochaperoning as a therapeutic strategy for the treatment of SLC6A1 -related disorders.

Transport mechanism and pharmacology of the human GlyT1

Dynamic role of GlyT1 as glycine sink or source: pharmacological implications for the gain control of NMDA receptors

Molecular basis for substrate recognition and transport of human GABA transporter GAT1

Cross-Linking and Functional Analyses for Dimerization of a Cysteine Mutant of Glycine Transporter 1

Glycine Uptake Regulates Hippocampal Network Activity via Glycine Receptor-Mediated Tonic Inhibition

The Role of N‐glycosylation in the Stability, Trafficking and GABA‐uptake of GABA‐transporter 1

Structural Mechanisms of Human Sodium-Coupled High-Affinity Choline Transporter CHT1

The role of N-glycosylation in the stability, trafficking and GABA-uptake of GABA-transporter 1. Terminal N-glycans facilitate efficient GABA-uptake activity of the GABA transporter.

A transporter's doom or destiny: SLC6A1 in health and disease, novel molecular targets and emerging therapeutic prospects

Glycine transporter-1 inhibitors: a patent review (2011–2016)

Ways of modulating GABA transporters to treat neurological disease

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

Dopamine reuptake and inhibitory mechanisms in human dopamine transporter

Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines

Towards Understanding the Interaction of Agonists with the Human Α1 Glycine Receptor

Glycine and glycine receptor signaling in hippocampal neurons: diversity, function and regulation.

Role of Glycine Receptors in Glycine-Induced LTD in Hippocampal CA1 Pyramidal Neurons

Structural features in the glycine-binding sites of the GluN1 and GluN3A subunits regulate the surface delivery of NMDA receptors

QSAR, ADMET In Silico Pharmacokinetics, Molecular Docking and Molecular Dynamics Studies of Novel Bicyclo (Aryl Methyl) Benzamides as Potent GlyT1 Inhibitors for the Treatment of Schizophrenia

Glucose Transporter 1, Distribution in the Brain and in Neural Disorders: Its Relationship with Transport of Neuroactive Drugs Through the Blood-Brain Barrier

Inhibitory Glycine Receptor